Overview

Therapy for Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder

Status:
Withdrawn
Trial end date:
2012-11-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine whether therapy that has been shown to be beneficial for mitochondrial diseases is also beneficial for Chronic Fatigue Syndrome (CFS) patients. This study is a chart review of previous CFS patients who received daily conditioning exercise, a high protein diet and nutraceutical therapy (ENT). Prescribed nutraceutical supplements included alpha-lipoic acid, acetyl-L-carnitine, omega-3fatty acids (maxDHA), coenzyme Q10 (CoQ10), plus a multivitamin. Twelve CFS male and female patients between the ages of 20-70 years will be recruited to participate in this pilot study. Subjects will be eligible to participate if they meet the criteria for CFS of the Centers for Disease Control and Prevention (CDC). These include persistent, unexplained fatigue for at least 6 months, concurrent with four of the following: impaired memory/concentration, sore throat, new headaches, unrefreshing sleep, muscle pain, multi-joint pain, tender lymph nodes, and post-exertional malaise.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Columbia University
Treatments:
Acetylcarnitine
Thioctic Acid
Criteria
Inclusion Criteria:

Severe chronic fatigue for 6 or more consecutive months 4 or more of the following 8
symptoms concurrently:

- post-exertion malaise lasting more than 24 hours

- unrefreshing sleep

- significant impairment of short-term memory or concentration

- muscle pain

- pain in the joints without swelling or redness

- headaches of a new type, pattern, or severity

- tender lymph nodes in the neck or armpit

- a sore throat that is frequent or recurring These symptoms should have persisted or
recurred during 6 or more consecutive months of illness and they cannot have first
appeared before the fatigue.

Exclusion Criteria:

- Additional medical illnesses causing chronic fatigue

- Ongoing exertion